We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
TMO Stock Benefits From New Bioprocess Design Center in Asia
Read MoreHide Full Article
Key Takeaways
TMO opened a new Hyderabad Bioprocess Design Center and expanded sites in Incheon and Singapore.
The tri-hub network aims to speed biologics production through innovation, training and expertise.
Shares rose 0.1% after the announcement as TMO strengthens support for Asia's growing biopharma market.
Thermo Fisher Scientific Inc. (TMO - Free Report) recently expanded its bioprocessing capabilities across Asia. The company introduced a new Bioprocess Design Center in Hyderabad, India, and expanded its existing centers in Incheon, Korea, and Singapore, further strengthening a strategic regional network designed to enhance speed, efficiency and sustainability in biomanufacturing.
The recent development reinforced its commitment to supporting the region’s rapidly growing biopharmaceutical industry. Together, these centers ensure customers have direct access to innovation, training, and technical expertise, enabling agility, scalability and faster time-to-market for biologics production.
Likely Trend of TMO Stock Following the News
Following the announcement, TMO shares rose 0.1% to close at $580.90 in yesterday’s after-market trading session.
Within the pharma and biotech end market, Thermo Fisher’s biosciences and bioproduction businesses have recently expanded capacity to meet global vaccine manufacturing needs. We expect the latest development to further boost the market sentiment toward TMO stock in the upcoming days.
Presently, Thermo Fisher boasts a market capitalization of $219.85 billion. The Zacks Consensus Estimate forecasts a 3.9% increase in the company’s earnings and 3.2% growth in revenues, both on a year-over-year basis. TMO beat on earnings in each of the trailing four quarters, delivering an earnings surprise of 2.3%.
Importance of TMO’s Expansion Into Asia
Asia is an emerging global hub for biopharmaceutical innovation, driven by increased demand for biologics, vaccines and cell and gene therapies. Thermo Fisher’s continued investment across the region supports this growth, giving customers access to world-class technologies, expertise and localized support to accelerate the delivery of life-changing therapies.
More on TMO’s Newly Expanded Bioprocess Design Centers
Thermo Fisher’s tri-hub network connects leading Bioprocess Design Centers in Incheon, Hyderabad and Singapore, accelerates process development and brings Thermo Fisher’s world-class expertise closer to customers throughout Asia.
The newly expanded Bioprocess Design Center at Incheon will empower deeper collaboration and innovation through advanced materials, technologies and enhanced lab capabilities. The new Bioprocess Design Center in Hyderabad, India (Genome Valley), has been developed in partnership with the Government of Telangana. It will offer collaborative spaces for process design, simulation and optimization. The facility will enable customers to co-create and test bioprocesses using the latest single-use and hybrid systems, further advancing India’s rapidly growing biomanufacturing ecosystem.
The center in Singapore will provide access to bench-to-pilot-scale bioprocessing, expert-led training, and deep collaboration with Thermo Fisher’s technical teams to help scale early-stage processes, supporting flexible and sustainable biomanufacturing.
Image Source: Zacks Investment Research
Industry Prospects Favor TMO
Per the Insight Partners report, the bioprocessing market size is projected to surge from $25.35 billion in 2023 to $72.55 billion by 2031. The market is estimated to register a CAGR of 14.0% during 2023-2031. The increasing prevalence of chronic diseases is driving market growth.
Another Recent Development by TMO
Last month, Thermo Fisher introduced the Thermo Scientific SureTect Beverage Spoilage Multiplex qPCR assay. The assay is an industry-first all-in-one quantitative Polymerase Chain Reaction (PCR)-based test developed in collaboration with Coca-Cola Europacific Partners.
TMO Stock Price Performance
In the past year, TMO shares have risen 8.6% against the industry’s 0.1% decline.
TMO’s Zacks Rank and Key Picks
Thermo Fisher currently carries a Zacks Rank #3 (Hold).
Estimates for Globus Medical’s EPS have increased 11.8% in the past 30 days. Shares of the company have risen 8.5% in the past year compared with the industry’s growth of 1.1%. GMED’s earnings surpassed estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 16.2%. In the last reported quarter, it delivered an earnings surprise of 49.4%.
Boston Scientific’s shares have jumped 12.3% in the past year. Estimates for the company’s 2025 EPS have increased 1 cent to $3.04 in the past 30 days. BSX’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 7.4%. In the last reported quarter, it posted an earnings surprise of 5.6%.
Estimates for MDT’s fiscal 2026 EPS of $5.65 have increased 0.5% in the past 30 days. Shares of the company have rallied 21.7% in the past year against the industry’s 0.1% decline. MDT’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 2.7%. In the last reported quarter, it delivered an earnings surprise of 3.8%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
TMO Stock Benefits From New Bioprocess Design Center in Asia
Key Takeaways
Thermo Fisher Scientific Inc. (TMO - Free Report) recently expanded its bioprocessing capabilities across Asia. The company introduced a new Bioprocess Design Center in Hyderabad, India, and expanded its existing centers in Incheon, Korea, and Singapore, further strengthening a strategic regional network designed to enhance speed, efficiency and sustainability in biomanufacturing.
The recent development reinforced its commitment to supporting the region’s rapidly growing biopharmaceutical industry. Together, these centers ensure customers have direct access to innovation, training, and technical expertise, enabling agility, scalability and faster time-to-market for biologics production.
Likely Trend of TMO Stock Following the News
Following the announcement, TMO shares rose 0.1% to close at $580.90 in yesterday’s after-market trading session.
Within the pharma and biotech end market, Thermo Fisher’s biosciences and bioproduction businesses have recently expanded capacity to meet global vaccine manufacturing needs. We expect the latest development to further boost the market sentiment toward TMO stock in the upcoming days.
Presently, Thermo Fisher boasts a market capitalization of $219.85 billion. The Zacks Consensus Estimate forecasts a 3.9% increase in the company’s earnings and 3.2% growth in revenues, both on a year-over-year basis. TMO beat on earnings in each of the trailing four quarters, delivering an earnings surprise of 2.3%.
Importance of TMO’s Expansion Into Asia
Asia is an emerging global hub for biopharmaceutical innovation, driven by increased demand for biologics, vaccines and cell and gene therapies. Thermo Fisher’s continued investment across the region supports this growth, giving customers access to world-class technologies, expertise and localized support to accelerate the delivery of life-changing therapies.
More on TMO’s Newly Expanded Bioprocess Design Centers
Thermo Fisher’s tri-hub network connects leading Bioprocess Design Centers in Incheon, Hyderabad and Singapore, accelerates process development and brings Thermo Fisher’s world-class expertise closer to customers throughout Asia.
The newly expanded Bioprocess Design Center at Incheon will empower deeper collaboration and innovation through advanced materials, technologies and enhanced lab capabilities. The new Bioprocess Design Center in Hyderabad, India (Genome Valley), has been developed in partnership with the Government of Telangana. It will offer collaborative spaces for process design, simulation and optimization. The facility will enable customers to co-create and test bioprocesses using the latest single-use and hybrid systems, further advancing India’s rapidly growing biomanufacturing ecosystem.
The center in Singapore will provide access to bench-to-pilot-scale bioprocessing, expert-led training, and deep collaboration with Thermo Fisher’s technical teams to help scale early-stage processes, supporting flexible and sustainable biomanufacturing.
Image Source: Zacks Investment Research
Industry Prospects Favor TMO
Per the Insight Partners report, the bioprocessing market size is projected to surge from $25.35 billion in 2023 to $72.55 billion by 2031. The market is estimated to register a CAGR of 14.0% during 2023-2031. The increasing prevalence of chronic diseases is driving market growth.
Another Recent Development by TMO
Last month, Thermo Fisher introduced the Thermo Scientific SureTect Beverage Spoilage Multiplex qPCR assay. The assay is an industry-first all-in-one quantitative Polymerase Chain Reaction (PCR)-based test developed in collaboration with Coca-Cola Europacific Partners.
TMO Stock Price Performance
In the past year, TMO shares have risen 8.6% against the industry’s 0.1% decline.
TMO’s Zacks Rank and Key Picks
Thermo Fisher currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Globus Medical (GMED - Free Report) , Boston Scientific (BSX - Free Report) and Medtronic (MDT - Free Report) . While Globus Medical sports a Zacks Rank #1 (Strong Buy), Boston Scientific and Medtronic carry a Zacks Rank #2 (Buy) each at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Estimates for Globus Medical’s EPS have increased 11.8% in the past 30 days. Shares of the company have risen 8.5% in the past year compared with the industry’s growth of 1.1%. GMED’s earnings surpassed estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 16.2%. In the last reported quarter, it delivered an earnings surprise of 49.4%.
Boston Scientific’s shares have jumped 12.3% in the past year. Estimates for the company’s 2025 EPS have increased 1 cent to $3.04 in the past 30 days. BSX’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 7.4%. In the last reported quarter, it posted an earnings surprise of 5.6%.
Estimates for MDT’s fiscal 2026 EPS of $5.65 have increased 0.5% in the past 30 days. Shares of the company have rallied 21.7% in the past year against the industry’s 0.1% decline. MDT’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 2.7%. In the last reported quarter, it delivered an earnings surprise of 3.8%.